Stable CAD (Coronary artery disease)

The optimal timing of the administration of P2Y12 inhibitors in patients with CCS undergoing ad-hoc PCI is unknown. This study aimed to provide observational data to clarify these quandaries.

This current study explored the effect of heavy particle pollution on total cardiovascular admissions, whilst also looking at risk for specific cardiovascular diagnoses, such as angina, myocardial infarction, and ischaemic stroke.

The objective of this analysis was to evaluate the impact of residual ischemia detected by post-PCI iFR on clinical outcomes and on residual-angina at the 12-month follow-up of the DEFINE PCI study.

This study evaluated the frequency and impact of periprocedural MI by using various MI definitions among patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI).

This study aimed to increase the power to detect differences in patient survival (freedom from cardiac deaths) with IVUS versus angiography guidance by pooling the individual patient data from the IVUS-XPL and ULTIMATE trials.

Watch this session to discover a selection of cases on miscellaneous coronary interventions unveiled at GulfPCR-GIM 2021: imaging-guided multivessel PCI in left main with TVD with rotablation in a ESRD, tiger catheter-induced left main occlusion, using IVL instead of rotational atherectomy, PCI of LIMA-LAD at anastomotic site in single surviving artery, aortocoronary dissection...

Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability of the FAME 3 trial presented at TCT 2021.

In this prespecified subgroup analysis of the AFIRE trial, the authors report the outcomes of rivaroxaban monotherapy compared to rivaroxaban and an antiplatelet agent in patients with atrial fibrillation who underwent coronary stenting > 1 year prior to enrolment.

The FUTURE Trial is a prospective randomised, multicentre, open label superiority trial comparing an FFR guided treatment strategy to traditional angiography guided treatment strategy on clinical outcomes in an all-comer population with multivessel coronary artery disease.

Nicola Ryan reviews the iFR Swedeheart multicenter, randomized, controlled, open-label clinical trial using the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) for enrolment randomisation and follow up. At one year follow up iFR guided revascularisation was shown to be non-inferior to FFR guided revascularisation, these results...